SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Speculation around a potential buyoutfueled by the CEOs anniversary message and the companys planned ASH presenceis competing with anticipation of a final analysis of SELLASs REGAL Phase 3 trial, last reported at 78 of 80 required events. Some traders read the prolonged trial and managements upbeat tone as encouraging, while others stress that no acquisition, event threshold, or trial result has been confirmed and that the recent price move may be trading without fresh news.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plan to pursue a public listing for its Monee financial-services arm is fueling debate as shares sell off. Some traders see the separation and uncertain timeline as an overhang that could leave Sea with less valuable businesses, while others argue shareholders could benefit from receiving Monee shares or from the business being valued separately.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings and outlook dominate discussion, with traders focused on subscriber engagement and growth, ad revenue, and the effect of recent layoffs and content-leadership changes. Views are sharply divided: some see low expectations and a chance for a rebound, while others fear further weakness, citing the stocks decline and its recent post-earnings performance.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for its persistent share-price weakness despite Orladeyo growth, with many traders criticizing management and the Astria acquisition while others argue the business is undervalued. The debate also focuses on upcoming product updates and Navenibart and Netherton data: bulls see potential catalysts, while skeptics question execution and face of HAE competition.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp has driven a sharp rally, with traders focused on the cash proceeds and potential balance-sheet and strategic benefits. The reaction is divided: some see a positive reset, while skeptics worry the divestiture removes a meaningful revenue business and leaves weaker operations and debt concerns.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE is selling off despite a quarterly earnings beat and higher full-year guidance, as traders focus on rising costs, weaker cash conversion, lower-margin sales and a loss in its insurance business; some also worry that engines are accumulating at Boeing ahead of aircraft deliveries. The reaction has frustrated bullish traders who see strong demand and orders, while others view the selloff as evidence that profitability and execution matter more than the headline beat.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta is drawing attention as shares rebound while traders look ahead to clinical readouts for its DM1 and FSHD siRNA programs, alongside discussion of Arrowhead data as a possible validation of the technology. Bulls see the pipeline as a potential growth driver, while skeptics say early or preclinical results still need to translate into meaningful patient benefit and question the stocks weak price action.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech-sector rebound is driving attention, with traders describing XBI as breaking out after a sharp pullback and citing renewed buying and possible rotation into biotech. Bulls see a recovery taking hold, while skeptics warn the bounce could fade amid rate and other macro headwinds.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 trial of RAP-219 in bipolar mania met its primary and secondary endpoints, driving a sharp burst of bullish attention. Traders are divided over whether the modest placebo-adjusted improvement and safety and discontinuation concerns make the result less compelling, with some viewing it as proof of concept and others expecting the rally to fade.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being discussed alongside expectations of Republican losses in the midterms and declining confidence in Trump, with many traders blaming the stocks political association and questioning the companys business value. The conversation is predominantly bearish, though some traders see a possible short-term bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Warrants (15/01/2031)

Neutral Sentiment

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$0.89
Prev Close	$0.8999
Open	$0.90
Dividend Yield	N/A
50-Day Moving Average	$0.9823
Beta	0.58
Avg. Volume	10,559.79
PE Ratio	N/A

52-Week High	$1.40
52-Week Low	$0.61
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BCTXL Fundamentals